Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 141.30 4.40
Tata Mot 428.65 4.24
Bhel 181.05 3.10
Tata Stl 418.80 1.22
Ntpc Ltd 123.05 0.37
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Indoco Remedies Limited
Indoco Remedies Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:532612NSE:INDOCOBloomberg:INDR@INReuters:INRM.BO
Market Lot: 1Face Value: 2ISIN Demat: INE873D01024
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
28-MAY-13 Indoco Remedies announced that its board of directors appointed Suresh G. Kare as a chairman of the Company for a further period of 5 years with effect from July 01, 2013. 28-MAY-13 Indoco Remedies, a India based Pharmaceuticals company, reported a rise in standalone net profit for the quarter ended March 2013. During the quarter, the profit of the company rose 2.55% to Rs 128.5 million from Rs 125.3 million in the same quarter last ...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Indoco Remedies gets USFDA nod to market Glimepiride tablets  -IRIS 18-Apr-13
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)31-Dec-2013(9)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 5315.106264.305601.30
Other Income6.808.9022.60
Total Income5321.906273.205623.90
Cost of goods sold4568.305373.204841.90
OPBDIT753.60900.00782.00
PAT393.40426.60463.50
Gross Block---
Equity capital184.30184.30122.87
EPS (Rs.)-4.635.03
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-11.10 - 103.6771.57 - 96.42
Debt / Equity (x)---
Operating margin (% of OI)14.214.313.9
Net margin (% of OI) 7.4 6.8 8.2
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Indoco House
166, CST Road
Kalina
Santacruz (East)
Mumbai
Maharashtra-400 098
PHONE
(022) 2654 1851 - 55
FAX
(022) 2652 3067
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer